PharmTech Europe News

Aesica adds development capability at Queenborough with the opening of a new purpose-built facility.

EMVO appointed Andreas Walter general manager effective April 2016.

The European Medicines Agency report provides an analysis of the health-technology assessment pilot program, which began in 2010 and completed in March 2016.

A team of Bristol-Myers Squibb scientists will work in a new laboratory at the National Institute of Bioprocessing Research and Training facility in Dublin, Ireland.

The taskforce will work to identify opportunities to advance therapy manufacturing and the supply chain in the UK.

The conference discussed key industry issues including serialization, innovation, and patient-centricity.

The European Medicines Board elects Christa Wirthumer-Hoche as chair of their Management Board.

The companies say the acquisition will assist in expediting the clinical development of RhoNova, a potential treatment targeting rhodopsin-linked autosomal dominant retinitis pigmentosa.

The EC approved the merger on March 10, 2016 on the condition that Teva and Allergan divest certain assets in Europe.

The agency has revised its good pharmacovigilance practices guide on risk management systems.

The collaboration is part of Innovate UK’s competition for the development of regenerative medicines.

Curida entered into a partnership with René Bommer, PhD, founder and owner of pharmAccel Consulting.

The directorate is looking for experts to join the European Pharmacopoeia network.

Innovations awarded at Pharmapack Europe include improvements for patient compliance and protection from errors, tampering, or misuse.

Regulatory, corporate restructuring, and manufacturing issues will challenge bio/pharma to meet the needs and expectations of patients around the world.

Intellectual challenge, job security, and opportunity for advancement contribute to employee happiness, but the ultimate prize may be a satisfactory salary for bio/pharma employees in Europe.

The portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK.

Baxter expands capacity for lyophilized cytotoxic oncology therapies at its fill/finish facility in Halle, Germany.

An ABPI report found a lack of quality candidates for high-skilled roles in areas such as bioinformatics, translational medicine, clinical pharmacology, and pathology.

Roche will invest in Switzerland but leave sites in Ireland, Spain, Italy, and the US as it focuses on lower-volume, specialized medicines.

The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.

The scheme aims to ensure that EMA and licensing authorities of EU member states will use the same IT system, based on a single data standard.

The European AIDS Vaccine Initiative has brought together leading HIV researchers from public organizations and biotech companies to develop protective and therapeutic HIV vaccines.

The authors look at key factors driving the risk-sharing agreements that have been implemented to reduce drug expenditures across Europe.

An industry-led strategy was launched in September 2015, in which senior experts from life-sciences and chemical companies set out how Scotland provides the infrastructure, connectivity, and academic excellence necessary to sustain a thriving manufacturing base.

Tomas Salmonson is re-elected as Chair of the Committee for Medicinal Products for Human Use.

The agency started the full operation of its medical literature monitoring on Sept. 1, 2015.

The trend towards personalized medicines in Europe requires a more integrated framework that regulates the approval of devices and diagnostics.

EMA’s revised guideline on the implementation of accelerated assessment is open for public consultation.

This move is expected to stimulate the exploration of many more medicines for use in children.